G6PD and T-cell acute lymphoblastic leukemia: Moreover, the mTOR inhibitor, everolimus, was reported to abrogate resistance to dexamethasone in T-cell acute lymphoblastic leukemia cells by reducing G6PD protein levels and enhancing ROS levels [55].